NCT00292526

Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: European Institute of Oncology · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.

Conditions

• Cardiotoxicity
• Chemotherapeutic Toxicity

Interventions

Type	Name	Description
DRUG	Enalapril	enalapril orally administered

Timeline

• Start date: 2000-11-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2006-02-16
• Last updated: 2017-02-09

Locations

1 site across 1 country: Italy